BioPALS

Compared to traditional HTS campaigns, BioPALS:

• Screens billions more molecules
• Reduces costs by 10-fold
• Is three times faster

We achieve this through:

• Efficiently triaging up to billions of compounds using AI-enhanced structure-based virtual screening driven by advanced structure-based technologies

• Purchasing or synthesizing the virtual hits and then confirming them in vitro using three orthogonal biophysical techniques – Grating-coupled interferometry (GCI), Differential scanning fluorimetry (DSF) and Ligand-observed NMR, or other adapted bioassays

• Completing the process by profiling the Hits in primary in vitro ADMET assays

BioPALS is lean, providing high quality hits in weeks at a fraction of the price compared to classical techniques. This data-rich process facilitates the hit-to-lead and lead optimization stages, paving a leaner route to the clinic.

With BioPALS, the boundaries of virtual screening are continuously extended by incorporating cutting-edge AI technologies to fully explore the continually expanding chemical universe.